ClinicalTrials.gg
RecruitingNCT07245927Updated Jul 6, 2026

Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism

An observational study in Pulmonary Embolism Acute Massive, sponsored by Supergene, LLC. Recruiting at 14 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Supergene, LLC · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Ages
18 Years and older
Sex
All
01

Study summary

The aim of FORPE Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with massive pulmonary embolism in routine clinical practice.

Read the detailed description

In November 2023 a multicenter, open-label, randomized non-inferiority trial of the efficacy and safety of the non-immunogenic staphylokinase (Fortelyzin®) compared with alteplase (Actilyse®) in patients with massive pulmonary embolism (FORPE) has been completed (NCT04688320).

FORPE trial is the first report of the non-immunogenic staphylokinase usage in patients with massive pulmonary embolism accompanied by unstable haemodynamics. Non-immunogenic staphylokinase was found to be non-inferior to alteplase (p=1.00). Non-immunogenic staphylokinase had high safety profile and did not cause the major bleeding. No cases of haemorrhagic stroke or major bleeding were recorded in the non-immunogenic staphylokinase group, whereas there were five cases (5%) of BARC type 3+5 bleedings in the alteplase group (p=0.026). All major bleedings and fatal intracranial haemorrhage in the alteplase group were registered only in 60 years old patients.

The unique mechanism of action of non-immunogenic staphylokinase allows it to be used in a single dose of 15 mg, regardless of the patient's body weight. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus that makes it convenient for use in emergency medicine.

The indication "massive pulmonary embolism" is included in the Instructions for medical use of the non-immunogenic staphylokinase. In routine clinical practice, the non-immunogenic staphylokinase is used for massive pulmonary embolism treatment since 2024.

The aim of FORPE Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with massive pulmonary embolism in routine clinical practice.

02

Conditions studied

  • Pulmonary Embolism Acute Massive

Browse trials for

Keywords

  • Pulmonary Embolism
03

In context

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

This study's planned enrollment of 20,000 is above the median of 361 across 366 observational studies indexed under Pulmonary Embolism.

Browse Pulmonary Embolism studies →

Lead sponsor

Supergene, LLC is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men and women aged 18 years and older with verified massive pulmonary embolism, who received a single intravenous bolus of the non-immunogenic staphylokinase (15 mg).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 years and older.
  • Verified diagnosis of massive pulmonary embolism (using computer tomography)
  • Signs of overload / dysfunction of the right ventricle (at least one) in combination with persistent arterial hypotension or shock
  • The time from the symptoms onset is no more than 14 days.
  • Thrombolysis with the non-immunogenic staphylokinase, 15 mg as a single intravenous bolus.

Exclusion criteria

Exclusion Criteria:

  • Increased risk of bleeding:

    • extensive bleeding at present or within the previous 6 months;
    • intracranial (including subarachnoid) hemorrhage at present or in history;
    • hemorrhagic stroke within the last 6 months;
    • a history of diseases of the central nervous system (including neoplasms, aneurysms);
    • intracranial or spinal surgical interventions within the last 2 months;
    • major surgery or major trauma within the previous 4 weeks;
    • recent puncture of an incompressible blood vessel (eg, subclavian or jugular vein);
    • severe liver disease, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis;
    • confirmed gastric or duodenal ulcer within the last 3 months;
    • neoplasm with an increased risk of bleeding;
    • simultaneous administration of Dabigatran without prior administration of idarucizumab;
    • arterial aneurysms, developmental defects of arteries / veins;
    • acute pancreatitis;
    • bacterial endocarditis, pericarditis;
    • suspicion of aortic dissecting aneurysm;
    • any other conditions, in the opinion of the investigator, associated with a high risk of bleeding.
  • Lactation, pregnancy.
  • Known to the non-immunogenic recombinant staphylokinase.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Non-immunogenic staphylokinase

    Drug: non-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®

    Drug: Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®

Interventions

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    The number of death from any causes during hospitalization

    Time frame: day 7 after drug administration

Secondary outcomes

  1. All-cause mortality

    The number of death from any causes during 30 days after drug administration

    Time frame: day 30 after drug administration

  2. Haemodynamic Collapse

    The number of haemodynamic collapses from any causes during 30 days after drug administration

    Time frame: day 30 after drug administration

  3. Recurrent Pulmonary Embolism

    The number of recurrent pulmonary embolism from any causes during 30 days after drug administration

    Time frame: day 30 after drug administration

  4. Pulmonary Artery Systolic Pressure Measures

    The efficacy is evaluated in terms of pulmonary artery systolic pressure after drug administration

    Time frame: baseline and day 2 after drug administration

Other outcomes

  1. Intracranial haemorrhage

    The number of intracranial haemorrhage during 30 days after drug administration

    Time frame: day 30 after drug administration

  2. Major bleedings

    The number of major bleedings (according to BARC classification type 3 and 5) during 30 days after drug administration

    Time frame: day 30 after drug administration

07

Study locations

14 of 14 sites recruiting
  • Belgorod Regional Clinical Hospital of St. Joseph
    Belgorod, Russia
    Recruiting
    • Sergey Konstantinov · Contact
  • Kuzbass Cardiology center
    Kemerovo, Russia
    Recruiting
    • Olga L. Barbarash, MD, Prof · Contact
  • Center of Neurology and Cardiology
    Kirov, Russia
    Recruiting
    • Oleg V. Soloviev, MD, prof · Contact
  • Lipetsk City Hospital No. 4 "Lipetsk-Med"
    Lipetsk, Russia
    Recruiting
    • Alexandr V. Lubavin, PhD · Contact
  • E.I. Chazov National Medical Research Center of Cardiology
    Moscow, 121552, Russia
    Recruiting
    • Sergey N. Tereschenko, MD, Prof · Contactstereschenko@yandex.ru · (495) 150-44-19
    • Sergey N. Tereschenko, MD, Prof · Principal investigator
  • F.I. Inozemtsev City Clinical Hospital
    Moscow, Russia
    Recruiting
    • Eugenia V. Tavlueva, PhD · Contact
  • Moscow Multidisciplinary Clinical Center "Kommunarka"
    Moscow, Russia
    Recruiting
    • Anastasia U. Lebedeva, Md, Prof · Contact
  • S.P. Botkin City Clinical Hospital
    Moscow, Russia
    Recruiting
    • Yuri V. Karabach, PhD · Contact
  • S.S. Yudin City Clinical Hospital
    Moscow, Russia
    Recruiting
    • Natalya V. Yasnopolskaya, MD, PhD · Contact
  • N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
    Nizhny Novgorod, Russia
    Recruiting
    • Galina V. Kovaleva · Contact
  • G.A. Zakharyin Clinical hospital №6
    Penza, Russia
    Recruiting
    • Mikhail V. Timofeev, MD, PhD · Contact
  • V.P. Polyakov Samara Regional Clinical Cardiology Dispensary
    Samara, Russia
    Recruiting
    • Dmitry V. Duplyakov, MD, prof · Contact
  • Tver Regional Clinical Hospital
    Tver', Russia
    Recruiting
    • Robert M. Rabinovich, MD, PhD · Contact
  • City Clinical Hospital of Emergency medicine №25
    Volgograd, Russia
    Recruiting
    • Eduard A. Ponomarev, MD, prof · Contact
08

References and documents

Publications

  • Kirienko AI, Leontyev SG, Tereschenko SN, Yavelov IS, Shakhnovich RM, Erlikh AD, Talibov OB, Yarovaya EB, Semenov AM, Semenov MP, Ivanov SV, Beregovykh VV, Archakov AI, Markin SS; FORPE study group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE. J Thromb Haemost. 2025 Feb;23(2):657-667. doi: 10.1016/j.jtha.2024.09.035. Epub 2024 Oct 23. PubMed 39454884 ↗
  • Leontyev SG, Yarovaya EB, Kutsenko VA, Ivlev OE, Soplenkova AG, Semenov AM, Semenov MP, Ivanov SV, Romashova YA, Markin SS. The Safety of Non-immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE. Health Sci Rep. 2025 May 19;8(5):e70826. doi: 10.1002/hsr2.70826. eCollection 2025 May. PubMed 40391253 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2027, 28 months after the start.

Of 160 observational studies under Pulmonary Embolism, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 105. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 24, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Oct 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07245927
Lead sponsor
Supergene, LLC
Collaborators
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Jun 1, 2025
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Sergey N. Tereschenko, MD, Prof.
Contact
stereschenko@yandex.ru
495-150-44-19 ext. +7
Sergey N. Tereschenko, MD, Prof.
principal investigator · E.I. Chazov National Medical Research Center of Cardiology
Sergey S. Markin, MD, Prof.
study director · LLC "SuperGene"

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion